Skip to main content

Manitoba Premier Greg Selinger is calling on Ottawa to participate in a study of so-called liberation therapy.

DARRYL DYCK/DARRYL DYCK/THE CANADIAN PRESS

Clinical trials of so-called liberation therapy for people with multiple sclerosis got a $5-million boost Tuesday from Manitoba, which has decided to partner with its neighbour to the west.

Saskatchewan announced late last year that it was going it alone after other provinces and the federal government showed reluctance to do trials without more preliminary research. It pledged $5-million and issued a call for proposals.

Manitoba Premier Greg Selinger noted that with Manitoba's money now on the table, the $10-million the Multiple Sclerosis Society of Canada originally asked Ottawa to pony up for national trials has been achieved.

Story continues below advertisement

"It would be excellent if all the governments participated in a multi-site proposal including the federal government," Mr. Selinger said when pressed on the timing of the announcement. The Manitoba Premier faces a provincial election in the fall.

"In the absence of that, what's the Plan B that will move the agenda forward? This is a strong Plan B."

The Premier said he still hopes others may join in but noted that MS patients don't want to wait years for answers. Even if the clinical trials get under way this year, it could be at least 2014 before the results are in.

Saskatchewan Premier Brad Wall welcomed the additional support

"The bigger the sample the better it is," he said.

"I just think this is a very positive day for MS patients … but also for people who would like to see governments - notwithstanding the stripe of the government - just work together when it makes a lot of sense, especially if they're neighbours."

Mr. Wall leads the small-c conservative Saskatchewan Party while Mr. Selinger is a New Democrat.

Story continues below advertisement

Arnold Naimark of the Manitoba Health Research Council said the timing is hard to predict, since the studies have yet to be designed. But a call for proposals will go out nationally and patients outside of Manitoba and Saskatchewan could very well be involved, he said.

He also said it's possible answers could be obtained sooner - either because results are so favourable or because problems turn up which make further testing of the procedure unwise.

Liberation therapy, also referred to as chronic cerebrospinal venous insufficiency treatment, was pioneered by Italian surgeon Paolo Zamboni.

A balloon angioplasty is used to widen a vein in the neck, which is thought to relieve a buildup of iron in the brain. Many Canadians have been travelling abroad to have the procedure.

Canada has a high incidence of multiple sclerosis. On a per capita basis, the largest number of people with the disease live in Atlantic Canada and the Prairies.

The MS Society was pleased with the announcement, but still focused on the need for national trials.

Story continues below advertisement

"On behalf of all Canadians living with MS, we are pleased that the Manitoba government has made multiple sclerosis a top-priority health issue," spokesman Stewart Wong said in an e-mailed response.

"Scientifically relevant clinical trials in multiple sclerosis typically take place across a broad range of sites. If a nationwide clinical trial is to take place, the Manitoba and Saskatchewan projects will be helpful in ensuring this aim could be achieved."

Mr. Selinger said the trials will be in several places and the idea is to select the best proposal, not necessarily one from Manitoba researchers, although Manitoba patients must be included.

Alberta and Newfoundland and Labrador have set aside more modest amounts to study patients treated elsewhere. New Brunswick is offering $500,000 to help those who want to receive the treatment somewhere else.

The MS Society has been reluctant to put money into clinical trials just yet and is funding other studies on things such as how to screen patients for liberation therapy.

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter